title: Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative.
abstract: The Mary S. Easton Center for Alzheimer's Disease Research (UCLA-Easton Alzheimer's Center) is committed to the "therapeutic imperative" and is devoted to finding new treatments for Alzheimer's disease (AD) and to developing technologies (biomarkers) to advance that goal. The UCLA-Easton Alzheimer's Center has a continuum of research and research-related activities including basic/foundational studies of peptide interactions; translational studies in transgenic animals and other animal models of AD; clinical research to define the phenotype of AD, characterize familial AD, develop biomarkers, and advance clinical trials; health services and outcomes research; and active education, dissemination, and recruitment activities. The UCLAEaston Alzheimer's Center is supported by the National Institutes on Aging, the State of California, and generous donors who share our commitment to developing new therapies for AD. The naming donor (Jim Easton) provided substantial funds to endow the center and to support projects in AD drug discovery and biomarker development. The Sidell-Kagan Foundation supports the Katherine and Benjamin Kagan Alzheimer's Treatment Development Program, and the Deane F. Johnson Alzheimer's Research Foundation supports the Deane F. Johnson Center for Neurotherapeutics at UCLA. The John Douglas French Alzheimer's Research Foundation provides grants to junior investigators in critical periods of their academic development. The UCLA-Easton Alzheimer's Center partners with community organizations including the Alzheimer's Association California Southland Chapter and the Leeza Gibbons memory Foundation. Collaboration with pharmaceutical companies, biotechnology companies, and device companies is critical to developing new therapeutics for AD and these collaborations are embraced in the mission of the UCLA-Easton Alzheimer's Center. The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research.
authors.affiliation: Department of Neurology, The Mary S Easton Center for Alzheimer's Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. jlcummings@mednet.ucla.edu
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Cummings
authors.forename: John
authors.initials: J
authors.lastname: Ringman
authors.forename: Karen
authors.initials: K
authors.lastname: Metz
mesh_terms: D000047:Academies and Institutes / Q000458:organization & administration / Q000592:standards*; D000544:Alzheimer Disease / Q000628:therapy; D035843:Biomedical Research; D006801:Humans; D015141:Los Angeles